New hope for Hard-to-Treat myeloma: teclistamab trial in japan

NCT ID NCT04696809

Completed Disease control Sponsor: Janssen Pharmaceutical K.K. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested teclistamab, a drug that helps the immune system find and attack myeloma cells, in 40 Japanese patients whose multiple myeloma had returned or stopped responding to treatment. The goal was to check safety and find the right dose in phase 1, then see how well it works in phase 2. The trial is now complete.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Teclistamab (a bispecific antibody that helps immune cells attack myeloma cells)
What this could lead to: If successful, this could provide a new treatment option for Japanese patients with multiple myeloma that has returned or not responded to other therapies.
What could go wrong: This is an early-phase trial with only 40 participants, so results may not apply to all patients. Side effects like cytokine release syndrome and other immune reactions are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid system neoplasm plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGIC MALIGNANCIES

Contacts and locations

Locations

Japanese Red Cross Medical Center

Shibuya City, 150-8935, Japan
Japanese Red Cross Osaka Hospital

Osaka, 543-8555, Japan
Kameda Medical Center

Chiba, 296-8602, Japan
Kobe City Medical Center General Hospital

Kobe, 650 0047, Japan
Kurume University Hospital

Kurume, 830-0011, Japan
Kyoto Kuramaguchi Medical Center

Kyoto, 603-8151, Japan
Nagoya City University Hospital

Nagoya, 467 8602, Japan
National Hospital Organization Hiroshima-Nishi Medical Center

Ōtake, 739-0696, Japan
National Hospital Organization Kumamoto Medical Center

Kumamoto, 860-0008, Japan
National Hospital Organization Matsumoto Medical Center

Matsumoto, 399-8701, Japan
National Hospital Organization Mito Medical Center

Higashiibaraki-gun, 311-3193, Japan
National Hospital Organization Okayama Medical Center

Okayama, 701-1192, Japan
Niigata Cancer Center Hospital

Niigata, 951-8566, Japan
Ogaki Municipal Hospital

Gifu, 503-8502, Japan
Osaka International Cancer Institute

Osaka, 541 8567, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.